PD-1 Antibody Combined Neoadjuvant Chemotherapy for Ovarian Cancer
Last updated on July 2021Recruitment
- Recruitment Status
- Recruiting
- Estimated Enrollment
- Same as current
Summary
- Conditions
- Anti-PD-1
- Neoadjuvant Chemotherapy
- Neoadjuvant Immunotherapy
- Ovarian Cancer
- Type
- Interventional
- Phase
- Phase 2
- Design
- Allocation: RandomizedIntervention Model: Parallel AssignmentMasking: None (Open Label)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 18 years and 75 years
- Gender
- Only males
Description
Not Provided
Not Provided
Tracking Information
- NCT #
- NCT04815408
- Collaborators
- Not Provided
- Investigators
- Study Chair: Jianwei Zhou, MD Second Affiliated Hospital of Zhejiang University School of Medicine
Get Well Soon